Authors

  • Axmatova K.A., Azizova D.M.

Keywords:

GMG-KoA reduktaza, multifokal ateroskleroz, tana vazni, qorin aylanasining o‘zgarishi, lipid almashinuvi, eksperimental model, ferment faolligi, abdominal semirish.

References

Д.М.Азизова, И.Р.Мавлянов, Р.А.Сабирова, М.У.Кулманова, А.Б.Солиев, Г.Ж.Жарылкасынова. Разработка новых подходов к коррекции гиперлипидемии с учётом изменения жирнокислотного состава сыворотки крови//Анализ риска здоровью. – 2020. - № 2. – С. 152-163. DOI: 10.21668/health.risk/2020.2.17

Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. (2010) 375: 132–40. doi: 10.1016/S0140-6736(09)61717-7

Goldstein, J.L., Brown, M.S. (2015). Regulation of the mevalonate pathway. Cell, 161(4), 658–669.

Grundy, S.M. (2016). LDL cholesterol: role in atherosclerosis and therapeutic targets. Circulation Research, 118(4), 692–700.

Libby, P. (2021). Inflammation in atherosclerosis. Nature, 420(6917), 868–874.

Zhang, Y. et al. (2017). The role of HMG-CoA reductase in lipid metabolism and atherosclerosis development: Experimental insights. Atherosclerosis Journal, 265, 220–228.

Cannon, C.P. et al. (2004). Intensive versus moderate lipid lowering with statins in coronary patients. NEJM, 350(15), 1495–1504.